Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2015

Open Access 01-12-2015 | Research article

How much of the productivity losses among psoriasis patients are due to psoriasis

Authors: Anssi Mustonen, Kalle Mattila, Mauri Leino, Leena Koulu, Risto Tuominen

Published in: BMC Health Services Research | Issue 1/2015

Login to get access

Abstract

Background

In previous studies, productivity losses have been measured specifically due to psoriasis or generally due to health problems in psoriasis patients. There is no information on the proportion of health related productivity losses that are due to psoriasis.
The aim of this study was to estimate the proportion of productivity losses due to psoriasis and due to other medical problems among employed psoriasis patients.

Methods

Patients visiting a tertiary level dermatological clinic during a one-year period due to psoriasis or psoriasis arthritis, who were employed, were selected to the study. A questionnaire was used to assess productivity losses during the previous month.

Results

Psoriasis accounted for 38% of the total lost productivity costs. One fifth of patients had been on sick leave (absenteeism) due to psoriasis and a third of patients worked despite being sick with psoriasis (presenteeism). Men had higher costs of presenteeism, but the costs of absenteeism due to psoriasis were lower for men than for women.

Conclusions

Productivity losses should be assessed disease specifically to avoid overestimations of the role of the disease on indirect costs. Our study shows that about a third of the lost productivity costs are due to psoriasis.
Literature
1.
Raval K, Lofland JH, Waters H, Piech CT. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol. 2011;10(2):189–96.PubMed
2.
Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23(2):208–11.PubMed
3.
Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935.CrossRefPubMedPubMedCentral
4.
Chan B, Hales B, Shear N, Ho V, Lynde C, Poulin Y, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13(4):192–7.CrossRefPubMed
5.
Pearce DJ, Singh S, Balkrishnan R, Kulkrani A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24–8.CrossRefPubMed
6.
Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075–82.PubMed
7.
Javitz HS, Ward MM, Farber E, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46(6):850–60.CrossRefPubMed
8.
Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol. 2012;22(2):238–45.PubMed
9.
Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212(2):137–44.CrossRefPubMed
10.
Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005–13.CrossRefPubMed
11.
Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511–8.CrossRefPubMed
12.
Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases–focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55–61.CrossRefPubMed
13.
Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford). 2012;51(9):1618–27.CrossRef
14.
Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102–10.CrossRefPubMed
15.
Schultz AB, Chen CY, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics. 2009;27(5):365–78.CrossRefPubMed
16.
Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4(2):559–68.PubMedPubMedCentral
17.
Ekelund M, Mallbris L, Qvitzau S, Stenberg B. A higher score on the dermatology life quality index. Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis: Acta Derm Venereol; 2013.
18.
Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–80.CrossRefPubMed
19.
Allen H, Bunn 3rd WB, Naim AB. The self-reported health and productivity burden of autoimmune disorders at a major self-insured employer. J Occup Environ Med. 2012;54(9):1049–63.CrossRefPubMed
20.
Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW. Presenteeism: critical issues. J Occup Environ Med. 2010;52(11):1055–67.CrossRefPubMed
21.
Hemp P. Presenteeism: at work–but out of it. Harv Bus Rev. 2004;82(10):49–58. 155.PubMed
22.
Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31(7):537–49.CrossRefPubMed
23.
Carrascosa JM, Pujol R, Dauden E, Hernanz-Hermosa JM, Bordas X, Smadia JA, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20(7):840–5.PubMed
24.
Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236–44.CrossRefPubMed
25.
Gosselin E, Lemyre L, Corneil W. Presenteeism and absenteeism: differentiated understanding of related phenomena. J Occup Health Psychol. 2013;18(1):75–86.CrossRefPubMed
26.
Robertson I, Leach D, Doerner N, Smeed M. Poor health but not absent: prevalence, predictors, and outcomes of presenteeism. J Occup Environ Med. 2012;54(11):1344–9.CrossRefPubMed
27.
Knies S, Candel MJ, Boonen A, Evers SM, Ament AJ, Severens JL. Lost productivity in four European countries among patients with rheumatic disorders: are absenteeism and presenteeism transferable? Pharmacoeconomics. 2012;30(9):795–807.CrossRefPubMed
28.
Braakman-Jansen LM, Taal E, Kuper IH, van de Laar MA. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford). 2012;51(2):354–61.CrossRef
29.
Zhang W, Anis AH. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol. 2011;30 Suppl 1:S25–32.CrossRefPubMed
30.
31.
Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343–53.CrossRefPubMed
32.
Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17(5):381–6.PubMed
33.
Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Baurcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011;22(6):337–47.CrossRefPubMed
Metadata
Title
How much of the productivity losses among psoriasis patients are due to psoriasis
Authors
Anssi Mustonen
Kalle Mattila
Mauri Leino
Leena Koulu
Risto Tuominen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2015
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-015-0752-0

Other articles of this Issue 1/2015

BMC Health Services Research 1/2015 Go to the issue

Research article

A mediation approach to understanding socio-economic inequalities in maternal health-seeking behaviours in Egypt

Research article

A survey of the availability, prices and affordability of essential medicines in Jiangsu Province, China

Research article

A systematic review comparing the costs of chiropractic care to other interventions for spine pain in the United States

Research article

Determinants of the intention to use e-Health by community dwelling older people

Research article

A qualitative study of factors influencing retention of doctors and nurses at rural healthcare facilities in Bangladesh

Research article

Point-of-care screening for syphilis and HIV in the borderlands: challenges in implementation in the Brazilian Amazon